OS Therapies Inc
OST-503
non-small cell lung cancer
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for OST-503 in non-small cell lung cancer are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“OST-503 Phase 2 non-small cell lung cancer candidate indications expanded to include pancreatic cancer following review of target vector antigens include all KRAS G12 position mutations, which represents 76% of all KRAS mutations in cancer.”